About Deoxynucleotidyltransferase terminal-interacting protein 1
Deoxynucleotidyltransferase terminal-interacting protein 1 (DNTTIP1) is a protein
from Homo sapiens identified by UniProt accession
Q9H147, 329 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Deoxynucleotidyltransferase terminal-interacting protein 1 |
|---|
| UniProt accession | Q9H147 |
|---|
| Gene | DNTTIP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 329 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- mean platelet volume · score 0.18
- platelet count · score 0.12
- non-small cell lung carcinoma · score 0.09
- neoplasm · score 0.09
- body height · score 0.07
- nonpapillary renal cell carcinoma · score 0.07
- hepatocellular carcinoma · score 0.07
- thrombocythemia 2 · score 0.06
- essential thrombocythemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9H147-F1 | alphafold | PREDICTED | 68.35 | — |
Amino-acid sequence (329 residues)
MGATGDAEQP RGPSGAERGG LELGDAGAAG QLVLTNPWNI MIKHRQVQRR GRRSQMTTSF TDPAISMDLL RAVLQPSINE EIQTVFNKYM KFFQKAALNV RDNVGEEVDA EQLIQEACRS CLEQAKLLFS DGEKVIPRLT HELPGIKRGR QAEEECAHRG SPLPKKRKGR PPGHILSSDR AAAGMVWKPK SCEPIRREGP KWDPARLNES TTFVLGSRAN KALGMGGTRG RIYIKHPHLF KYAADPQDKH WLAEQHHMRA TGGKMAYLLI EEDIRDLAAS DDYRGCLDLK LEELKSFVLP SWMVEKMRKY METLRTENEH RAVEAPPQT
Explore Deoxynucleotidyltransferase terminal-interacting protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets